

FORM PTO-1449 (REV.7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 210121.427C9	APPLICATION NO. 09/439,313
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>		APPLICANTS Jiangchun Xu et al.			
		FILING DATE November 12, 1999	GROUP ART UNIT 1642		

U.S. PATENT DOCUMENTS

TECH CENTER 1600

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<i>AK</i>	AA 5,786,148	07/28/98	Bandman et al.	435	6	

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO
<i>AB</i>	DE 19649207	11/27/96	Germany		X
<i>AC</i>	EP 317 141 A2	05/24/89	EPO		
<i>AD</i>	EP 652 014 A1	5/10/95	EPO		
<i>AE</i>	EP 936 270 A2	08/18/99	EPO		
<i>AF</i>	WO 93/14755	08/05/93	PCT		
<i>AG</i>	WO 93/25224	12/23/93	PCT		
<i>AH</i>	WO 94/09820	05/11/94	PCT		

OTHER PRIOR ART *(Including Author, Title, Date, Pertinent Pages, Etc.)*

<i>AI</i>	Ahn and Kunkel, "The structural and functional diversity of dystrophin," <i>Nature Genetics</i> 3: 283-291, April, 1993.
<i>AJ</i>	Alexeyev et al., "Improved antibiotic-resistance gene cassettes and omega elements for <i>Escherichia coli</i> vector construction and in vitro deletion/insertion mutagenesis," <i>Gene</i> 160:63-67, 1995.
<i>AK</i>	Blok et al., "Isolation of cDNA that are differentially expressed between androgen-dependent and androgen-independent prostate carcinoma cells using differential display PCR," <i>The Prostate</i> 26:213-224, 1995.
<i>AL</i>	Cawthon et al., "cDNA sequence and genomic structure of EVI2B, a gene lying within an intron of the neurofibromatosis type 1 gene," <i>Genomics</i> 9:446-460, 1991.
<i>AM</i>	Chu et al., "CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity," <i>J. Exp. Med.</i> 186(10): 1623-1631, November 17, 1997.
<i>AN</i>	Coleman et al., <i>Fundamental Immunology</i> , Wm. C. Brown Publishers, Dubuque, Iowa, 1989, pp. 465-466.
<i>AO</i>	Database EMBL Accesion No. AA453562, June 11, 1997, Hillier et al., "Homo sapiens cDNA clone 788180."

EXAMINER	DATE CONSIDERED
<i>Sharon</i>	6/29/01

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449
(REV.7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
210121.427C9APPLICATION NO.
09/439,313**INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

APPLICANTS

Jiangchun Xu et al.

FILING DATE

November 12, 1999

GROUP ART UNIT

1642

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
-------------------	-----------------	------	------	-------	----------	----------------------------

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO
R	BA WO 95/04548	02/16/95	PCT		
R	BB WO 95/14772	06/01/95	PCT (Cover page with English abstract only)		X
R	BC WO 95/30758	11/16/95	PCT		
R	BD WO 96/21671	07/18/96	PCT		
R	BE WO 97/33909	09/18/97	PCT	OCT 17 2000 RECEIVED USPTO LIBRARY	
R	BF WO 98/12302	03/26/98	PCT		
R	BG WO 98/17687	04/30/98	PCT		
R	BH WO 98/20117	05/14/98	PCT		

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

R	BI	Derwent Geneseq Database, Accession No. V58522, December 8, 1998.
R	BJ	Derwent Geneseq Database, Accession No. V61287, January 6, 1999.
R	BK	Duerst and Nees, "Nucleic acid characteristic of late or early passage cells immortalized by papilloma virus-and related polypeptide(s) and antibodies, used for diagnosis and treatment of cervical cancer and assessing potential for progression of cervical lesions," Derwent World Patent Index, Accession No. 1998-121623, 1998. See also German Patent DE 19649207 C1.
R	BL	El-Shirbiny, "Prostatic Specific Antigen, <i>Advances In Clinical Chemistry</i> 31:99-133, 1994.
R	BM	Ezzell, C., "Cancer vaccines: an idea whose time has come?" <i>The Journal of NIH Research</i> 7:46-49, January, 1995.
R	BN	Harris et al., "Polycystic Kidney Disease 1: identification and analysis of the primary defect," <i>J. Am. Soc. of Nephrol.</i> 6:1125-1133, 1995.
R	BO	Hillier et al., Genbank Accession No. AA100799, December 23, 1997.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449
(REV.7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
210121.427C9APPLICATION NO.
09/439,313

RECEIVED

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS

Jiangchun Xu et al.

OCT 20 2000

FILING DATE

November 12, 1999

GROUP ART UNIT

1642

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
-------------------	--	-----------------	------	------	-------	----------	----------------------------

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
R	CA	WO 98/31799	07/23/98	PCT		
R	CB	WO 98/37093	08/27/98	PCT		
R	CC	WO 98/37418	08/27/98	PCT		
A	CD	WO 98/38310	09/03/98	PCT		
R	CE	WO 98/39446	09/11/98	PCT		
R	CF	WO 98/45435	10/15/98	PCT		
A	CC	WO 98/50567	11/12/98	PCT		
R	CH	WO 99/06548	02/11/99	PCT		

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

R	CI	Hillier et al., Genbank Accession No. R20590, April 18, 1995.
R	CJ	Hudson, T., Genbank Accession No. G22461, May 31, 1996.
R	CK	Kroger, B. "New serine protease form human prostate, useful for identifying specific inhibitors, antibodies and probes," Derwent World Patent Index, Accession No. '99-432218, 1999. See also European Patent EP 936 270 A2.
R	CL	National Cancer Institute, Cancer Genome Anatomy Project (NCI-CGAP), Genbank Accession No. AA551449, September 5, 1997.
R	CM	National Cancer Institute, Cancer Genome Anatomy Project (NCI-CGAP), Genbank Accession No. AA551759, August 11, 1997.
R	CN	National Cancer Institute, Cancer Genome Anatomy Project (NCI-CGAP), Genbank Accession No. AA631143, October 31, 1997.
R	CO	National Cancer Institute, Cancer Genome Anatomy Project (NCI-CGAP), Genbank Accession No. AA653016, November 25, 1997.

EXAMINER

St. John

DATE CONSIDERED

6/29/01

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV.7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 210121.427C9	APPLICATION NO. 09/439,313
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>		APPLICANTS Jiangchun Xu et al.	
		FILING DATE November 12, 1999	GROUP ART UNIT 1642

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
-------------------	--	-----------------	------	------	-------	----------	----------------------------

FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY		TRANSLATION	
				OIE	OCT 17 2000	YES	NO
<i>AS</i>	DA	WO 99/06552	02/11/99	PCT			
<i>AC</i>	DB	WO 99/25825	05/27/99	PCT			
<i>AC</i>	DC	WO 99/31236	06/24/99	PCT			
	DD						

OTHER PRIOR ART *(Including Author, Title, Date, Pertinent Pages, Etc.)*

<i>AS</i>	DE	Robson et al., "Indentification of prostatic adrogen regulated genes using the differential display technique," <i>Proceeding of the American Association for Cancer Research Meeting</i> 86, 36: p.266, Abstract No. 1589,1995.
<i>AC</i>	DF	Short et al., "λ ZAP: a bacteriophage λ expression vector with <i>in vivo</i> excision properties," <i>Nucleic Acids Research</i> 16(15):7583-7600, 1988.
<i>AS</i>	DG	Sjögren, H., "Therapeutic Immunization Against Cancer Antigens Using Genetically Engineered Cells," <i>Immunotechnology</i> 3: 161-172, 1997.
<i>AC</i>	DH	Zitvogel et al., "Eradication of Established Murine Tumors Using a Novel Cell-Free Vaccine: Dendritic Cell-Derived Exosomes," <i>Nature Medicine</i> 4(5): 594-600, May, 1998.
	DI	
	DJ	
	DK	
	DL	
	DM	

EXAMINER <i>Sh. Shor</i>	DATE CONSIDERED <i>6/29/51</i>
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).	

FORM PTO-1449 (REV.7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 210121.427C9	APPLICATION NO. 09/439,313
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>		APPLICANTS Jiangchun Xu et al.			
		FILING DATE November 12, 1999		GROUP ART UNIT 1642	

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	EA						
	EB						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION
			OIE OCT 17 2000 PATENTS & TRADEMARKS	YES NO
	EC			
	ED			
	EE			

OTHER PRIOR ART *(Including Author, Title, Date, Pertinent Pages, Etc.)*

<i>R</i>	EF	Berthon et al., "Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43," <i>Am. J. Hum. Genet.</i> 62(6):1416-1424, June 1998.
<i>R</i>	EG	Busselmakers et al., Genbank Accession No. AF103907, August 14, 2000.
<i>A</i>	EH	Busselmakers et al., Genbank Accession No. AF103908, August 14, 2000.
<i>A</i>	EI	Hara et al., "Characterization of cell phenotype by a novel cDNA library subtraction system: expression of CD8α in a mast cell-derived interleukin-4-dependent cell line," <i>Blood</i> 84(1):189-199, July 1, 1994.
<i>R</i>	ES	Lalvani et al., "Rapid effector function in CD8 ⁺ memory cells," <i>J. Exp. Med.</i> 186(6):859-865, September 15, 1997.
<i>A</i>	EK	Nelson et al., Genbank Accession No. NP_004908, March 18, 2000.
<i>R</i>	EL	Schena et al., "Parallel human genome analysis: Microarray-based expression monitoring of 1000 genes," <i>Proc. Natl. Acad. Sci. USA</i> 93(19):10614-10619, September 17, 1996.
<i>R</i>	EM	Sherman et al., "Selecting T cell receptors with high affinity for self-MHC by decreasing the contribution of CD8," <i>Science</i> 258(5083):815-818, October 30, 1992.

EXAMINER	DATE CONSIDERED
<i>M. H. T.</i>	<i>5/29/01</i>

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV.7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 210121.427C9	APPLICATION NO. 09/439,313
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>		APPLICANTS Jiangchun Xu et al.			
		FILING DATE November 12, 1999		GROUP ART UNIT 1642	

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	FA						
	FB						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COPYRIGHT OCT 17 2000 PATENT & TRADEMARK OFFICE	TRANSLATION
					YES NO
	FC				
	FD				
	FE				

OTHER PRIOR ART *(Including Author, Title, Date, Pertinent Pages, Etc.)*

<i>R</i>	FF	Smith et al., "Major susceptibility locus for prostate cancer on chromosome 1 suggested by genome-wide search," <i>Science</i> 274(5291), 1371-1374, November 22, 1996.
<i>R</i>	FG	Theobald, et al., "Targeting p53 as a general tumor antigen," <i>Proc. Natl. Sci. USA</i> 92(25):11993-11997, December 5, 1995.
<i>R</i>	FH	Tusnady and Simon, "Principles governing amino acid compositions of integral membrane proteins: application to topology prediction," <i>J. Mol. Biol.</i> 283(2):489-506, October 23, 1998.
<i>A</i>	FI	Van Tsai et al., " <i>In vitro</i> immunization and expansion of antigen-specific cytotoxic T lymphocytes for adoptive immunotherapy using peptide-pulsed dendritic cells," <i>Critical Reviews in Immunology</i> 18:65-75, 1998.
<i>R</i>	FJ	Vasmatzis et al., "Discovery of three genes specifically expressed in human prostate by expressed sequence tag database analysis," <i>Proc. Natl. Acad. Sci. USA</i> 95(1):300-304, January 6, 1998.
<i>R</i>	FK	Yee et al., "Isolation of tyrosinase-specific CD8 ⁺ and CD4 ⁺ T cell clones from the peripheral blood of melanoma patients following <i>in vitro</i> stimulation with recombinant vaccinia virus," <i>The Journal of Immunology</i> 157(9):4079-4086, November 1, 1996.
	FL	
	FM	

EXAMINER	DATE CONSIDERED
<i>D. K. Shao</i>	<i>6/29/5</i>
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).	